Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Some patients with later-onset spinal muscular atrophy (SMA) type 2 and type 3 had improved motor function when the investigational monoclonal antibody apitegromab was added

Bay­er is “ba­si­cal­ly halv­ing” the size of its phar­ma­ceu­ti­cal lead­er­ship team, a spokesper­son told End­points News, as the com­pa­ny be­gins to roll out a re­struc­tur­ing